Medical Doctor Program year 2023 Source: CMS Open Payments, 2026 publication

Stella Chen

Dermatology Phoenix, AZ Medical Doctor

NPI 1023673894 CMS profile 11468470

5777 E Mayo Blvd, Phoenix, AZ 85054

Open in the dashboard

General payments

$409

6 records reported · program year 2023

Research payments

$0

Paid to them · None reported · program year 2023

Ownership & investment interest

$0

None reported

Through program year 2023, Stella Chen of Phoenix, AZ is reported in the CMS Open Payments database as having received $409 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 22nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2023 General $409 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stella Chen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stella Chen were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stella Chen Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $409 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program year 2023
  1. Janssen Biotech, Inc. $100 1 payment
  2. AbbVie, Inc. $94 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $83 1 payment
  4. LEO Pharma Inc. $64 1 payment
  5. E.R. Squibb & Sons, L.L.C. $44 1 payment
  6. Gilead Sciences, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program year 2023
  1. Food and Beverage $309 5 payments
  2. Education $100 1 payment
Products named General payments · program year 2023
  1. TREMFYA $100 1 payment
  2. STELARA $100 1 payment
  3. RINVOQ $94 1 payment
  4. ADBRY $64 1 payment
  5. SOTYKTU $44 1 payment
  6. Trodelvy $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

427

Median for Dermatology: 534

Drug cost

$454,169

Median for Dermatology: $67,151

Branded share of claims

23.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 12 $272,776
Dupixent Pen Dupilumab Brand 25 $111,486
Dupixent Syringe Dupilumab Brand 15 $60,195
Fluorouracil Generic 37 $1,747
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 25 $1,744
Triamcinolone Acetonide Generic 89 $1,120
Ketoconazole Generic 74 $1,092
Metronidazole Generic 14 $827
Clobetasol Propionate Generic 20 $823
Betamethasone Dipropionate Generic 18 $764

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$122,820

Of which drugs: $11,702

Medicare patients

652

Average age 75

Services billed

2,956

353 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 42%
Ischemic heart disease 27%
Chronic kidney disease 23%
Osteoporosis 23%
Diabetes 21%
Cancer 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 20 31 $9,633
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 107 $77

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record